Without communication you can’t move forward. Digitalization and new technologies have made information exchange easier over the last century, but there is still room for improvement. With that in mind, since Spanish Association of Generic Medicines (Aeseg) consider the reform of the European Medicines Strategy, currently being discussed in the European Parliament, to be a “good opportunity” to improve communication between them European Medicines Agency (EMA) and the National companies in this case the Spanish ones.
“We are at a moment where technologies have made important advances, we can take advantage of this and have one.” better communication between the EMA and national companies. So that we can be more fast, flexible and ready for use” said Ángel Luis Rodríguez de la Cuerda, Secretary General of Aeseg.
In fact, generics play a big role in the reform that is being carried out in the European Union. One of the aspects that this package includes is that Reindustrialization of the old continent “guarantee a open strategic autonomy and sustainable pharmaceutical policies for access, availability and affordability.
European reindustrialization
In the words of Rodríguez de la Cuerda, it is a good framework for leadership Measures that enable prediction “We have clear goals, such as returning to the current risk lack of medication supply. “In the new pharmaceutical legislation there are very concrete proposals such as the reindustrialization of our sector and the attraction of investments,” explains the Secretary General of Aeseg. “The idea is are not so dependent on third countries and achieve greater investment in member countries, thereby achieving a positive impact on gross domestic product (GDP) and an increase in employment,” he adds.
Likewise from the Spanish generic that they advocate Secure your medications, as they are “essential products”. One way to do this is Increase penetration rates and secure inventory. At the Spanish level, the share of the generic market is 41 percent in units and 20 percent in values; while the European average is 65 percent in units and 25 percent in values, figures that they want to achieve on the Spanish market. With this in mind, Medicines for Europe, the European employers’ association for generics and biosimilars, has emphasized more “Predictability and legal certainty” to ensure all patients have access to their medication.
In addition, Spain can also act Speaker for the benefit of the pharmaceutical industry, as she currently holds the European presidency until December. Health measures on the agenda include: strengthening public health systems, the Management of “Big Data” in the industry the concept of One Health and multidisciplinarity in health professions.
The information published in Medical Writing contains opinions, data and statements from official institutions and health professionals. However, if you have any questions about your health, please contact your local health professional.
